Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundMalen = 10 mice per time point per group in triplicate independent…Topical application to the wound20 microlitres of 10, 20 or 40 micromolar peptide; EGF posi…Applied after wounding, with wound area measured on days 4, 7 and 10
Model: Two 8 x 8 mm full-thickness skin wounds on the back of each anaesthetised mouse; in vitro scratch wounds in HaCaT and HSF monolayers
Topical peptide at 20 and 40 micromolar accelerated wound closure (residual wound 32%, 15.02% and 6.63% versus vehicle 53.5%, 35.3% and 15.6% on days 4, 7 and 10), with faster re-epithelialisation, greater macrophage and TGF-beta1 positive cell counts and no haemolytic or acute toxic effect.
Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.